ADIM
AGYS icon

Alpha DNA Investment Management’s Agilysys AGYS Stock Holding History

Alpha DNA Investment Management’s Portfolio AGYS Stock Details AGYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,538
Closed -$470K – 196
2023
Q4 		$470K Buy
+5,538
New +$450K 0.18% 142

Other funds holding AGYS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GCM
Geneva Capital Management Milwaukee, Wisconsin $4.71B AUM 6.32% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Alpha DNA Investment Management's AGYS Position: Q1 2024 in Review

Alpha DNA Investment Management sold out of Agilysys (AGYS) in Q1 2024, closing a stake of 5,538 shares — an estimated $470K sold.

Alpha DNA Investment Management first reported a position in AGYS in Q4 2023 and held it in 1 quarter. The position peaked at $470K in Q4 2023. 231 funds tracked by Wall St. Rank hold AGYS as of Q1 2024.

  • Alpha DNA Investment Management reported no remaining Agilysys position as of Q1 2024 after selling out during the quarter.
  • Alpha DNA Investment Management sold 5,538 Agilysys shares in Q1 2024, an estimated $470K.
  • Alpha DNA Investment Management first reported a position in Agilysys in Q4 2023 and held it in 1 quarter.
  • Alpha DNA Investment Management's Agilysys position peaked at $470K in Q4 2023.
  • 231 funds tracked by Wall St. Rank held Agilysys as of Q1 2024.

Based on Alpha DNA Investment Management's 13F filing for Q1 2024, filed 15 May 2024.